what is the duration lhrh agonist therapy with salvge rth in prostate cancer?

GPT-5.4

Answer: The usual duration of LHRH agonist therapy with salvage radiotherapy in prostate cancer is about 4–6 months, with extension to around 24 months considered for selected higher-risk patients.

I maintain my prior position because the other models largely reinforced it rather than changed it. There is broad agreement across the responses that the most typical evidence-based duration in the salvage post-prostatectomy setting is short-course ADT, most commonly 6 months and often summarized as 4–6 months. What supports this most directly is the trial evidence using an actual LHRH agonist in the salvage setting, especially GETUG-AFU 16, which used 6 months of goserelin. That makes 6 months the clearest single answer if forced to give one number. At the same time, phrasing the answer as 4–6 months remains more accurate clinically, because short-course practice patterns and guideline language are often expressed that way rather than as one rigid duration. The other models also correctly note that some patients may receive longer treatment, especially those with higher-risk features such as higher pre-salvage PSA, more aggressive pathology, rapid PSA doubling time, or nodal-risk situations. The key nuance is that the strongest older long-course salvage data, such as RTOG 9601, used bicalutamide rather than an LHRH agonist, so one should be careful not to overstate that as direct evidence for long-duration LHRH agonist specifically. Still, in modern practice, the general principle of intensifying hormonal therapy in selected higher-risk patients is accepted. So my answer stays essentially the same: if the question asks for the typical duration, the best concise response is 4–6 months, with 6 months as the common standard reference point, while acknowledging that higher-risk cases may be treated longer, often up to 24 months.

Grok 4.20

Answer: The typical duration of LHRH agonist therapy with salvage radiotherapy in prostate cancer is 6 months for most patients, extendable to 18-24 months in higher-risk cases.

My initial position focused on 6 months as the evidence-based standard, drawn from trials like GETUG-AFU 16 showing benefits in progression-free and metastasis-free survival with this duration alongside salvage RT. Reviewing the other models' answers reveals strong consistency rather than contradiction: all cite the same key trials (GETUG-AFU 16 for 4-6 months, RTOG 9601 and RADICALS-HD informing longer courses for high-risk features like elevated PSA or adverse pathology), and they converge on 4-6 months as the common default while allowing personalization. This alignment with NCCN/EAU guideline nuances reinforces my view instead of shifting it, as the core answer remains that 6 months represents the most frequently applied duration in the salvage setting to balance efficacy against side effects. No single response introduced compelling new evidence that would alter the headline typical duration from 6 months.

Gemini 3.1 Pro

Answer: The standard duration of LHRH agonist therapy combined with salvage radiotherapy for prostate cancer is typically 4 to 6 months, though high-risk patients often benefit from an extended course of 18 to 24 months.

I maintained my position because the other models reinforced the evidence-based consensus that 4 to 6 months of LHRH agonist therapy is the baseline standard, while longer durations are appropriate for higher-risk cases. The GETUG-AFU 16 and SPPORT (NRG/RTOG 0534) trials established short-course androgen deprivation therapy (ADT) lasting 4 to 6 months as the standard of care for most men undergoing salvage radiotherapy (SRT). Adding this brief hormonal blockade significantly improves metastasis-free and biochemical progression-free survival compared to radiation alone, without causing the severe, long-term toxicities associated with prolonged testosterone suppression. However, a "one-size-fits-all" approach does not apply. For patients presenting with high-risk features—such as a pre-salvage PSA greater than 0.6 or 0.7 ng/mL, high Gleason scores, or a rapid PSA doubling time—data from trials like RTOG 9601 and RADICALS-HD suggest that extending therapy to 18 to 24 months offers superior long-term oncologic outcomes, including potential overall survival benefits. Ultimately, selecting between a 4-to-6-month and an 18-to-24-month duration requires shared decision-making. Clinicians must weigh the oncologic benefits of prolonged LHRH agonist therapy against its well-documented adverse cardiovascular, metabolic, and quality-of-life impacts. Furthermore, emerging tools like genomic classifiers (e.g., Decipher) are increasingly being utilized to personalize this duration based on the patient's exact molecular risk profile.

Claude Opus 4.7 (changed mind)

Answer: For salvage radiotherapy after radical prostatectomy, the LHRH agonist is typically given for 4–6 months in most patients, with 24 months reserved for those with higher-risk features.

My position is essentially unchanged, and the other models converge on the same framework, which reinforces rather than alters my answer. The evidence base remains GETUG-AFU 16 (6 months of goserelin with SRT) for short-course therapy and RTOG 9601 (24 months of bicalutamide) for longer-duration therapy in higher-risk patients, with the SPPORT (NRG/RTOG 0534) trial — which Gemini 3.1 Pro helpfully highlighted — further supporting short-course ADT plus SRT (with or without pelvic nodal RT). Gemini 3.1 Pro's mention of RADICALS-HD is a useful addition: its results suggest that 24 months is superior to 6 months for men with adverse features (higher pre-SRT PSA, Gleason 8–10, short PSA doubling time), while 6 months remains adequate for lower-risk biochemical recurrence. This aligns with, rather than contradicts, my prior answer. I would slightly refine the phrasing from my round 1 answer: rather than '6 months for most, 24 months considered for higher risk,' the more precise formulation is '4–6 months as the short-course standard, 24 months for higher-risk patients,' which better reflects guideline language (NCCN, EAU) and the SPPORT/GETUG-AFU 16/RADICALS-HD evidence. Duration should still be individualized based on pre-SRT PSA, pathology, PSA doubling time, comorbidities, and increasingly genomic classifiers such as Decipher. This remains general information, not individualized medical advice.

Final Summary

The AI Roundtable reached a consensus that therapy duration is risk-dependent, typically lasting 4 to 6 months for most patients. Gemini 3.1 Pro and Claude Opus 4.7 noted that for high-risk cases—such as those with high PSA levels or aggressive pathology—the duration is extended to 18 to 24 months. GPT-5.4 and Grok 4.20 highlighted that the 6-month standard, rooted in the GETUG-AFU 16 trial, balances treatment efficacy with the side effects of hormone suppression.

All 4 models agreed